Neurocognitive effects of repetitive transcranial magnetic stimulation in adolescents with major depressive disorder.

ABSTRACT:

Objectives

It is estimated that 30-40% of adolescents with major depressive disorder (MDD) do not receive full benefit from current antidepressant therapies. Repetitive transcranial magnetic stimulation (rTMS) is a novel therapy approved by the US Food and Drug Administration to treat adults with MDD. Research suggests rTMS is not associated with adverse neurocognitive effects in adult populations; however, there is no documentation of its neurocognitive effects in adolescents. This is a secondary post hoc analysis of neurocognitive outcome in adolescents who were treated with open-label rTMS in two separate studies.

Methods

Eighteen patients (mean age, 16.2 ± 1.1 years; 11 females, 7 males) with MDD who failed to adequately respond to at least one antidepressant agent were

SUBMITTER: Wall CA 

PROVIDER: S-EPMC3859914 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature